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Development and characterization of benznidazole nano- and microparticles: A new
tool for pediatric treatment of Chagas disease?, Colloids and Surfaces B: Biointerfaces
(2019), https://doi.org/10.1016/j.colsurfb.2019.01.039
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
1 
 
Development and characterization of benznidazole nano- and 
microparticles: A new tool for pediatric treatment of Chagas disease? 
 
Katia P. Seremeta a,b, Eva C. Arrúa c,d, Nora B. Okulik a,b, Claudio J. Salomonc,d,* 
 
a Departamento de Ciencias Básicas y Aplicadas, Universidad Nacional del 
Chaco Austral, Cte. Fernández 755, 3700, Pcia. Roque Sáenz Peña, Chaco, 
Argentina. 
b Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Pcia. 
Roque Sáenz Peña, Chaco, Argentina 
c Instituto de Química Rosario, Consejo Nacional de Investigaciones Científicas 
y Técnicas (IQUIR-CONICET), Suipacha 531, 2000, Rosario, Argentina  
d Área Técnica Farmacéutica, Departamento de Farmacia, Facultad de Ciencias 
Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, 
Argentina 
 
*Corresponding autor at: Instituto de Química Rosario, Consejo Nacional de 
Investigaciones Científicas y Técnicas (IQUIR-CONICET), Suipacha 531, 2000, 
Rosario, Argentina. Tel.: +54 341 4804592; Fax: +54 341 4370477. 
E-mail addresses: csalomon@fbioyf.unr.edu.ar, claudiosalomon@hotmail.com 
(C.J. Salomon). 
Statistical summary of the article 
 
Total number of words: 5900  





















 Benznidazole nano/microparticles were obtained by freeze/spray-drying, 
respectively. 
 Benznidazole nanoparticles were obtained in size range of 200-300 nm. 
 Benznidazole microparticles exhibited a size range between 0.87 and 1.26 
m. 
 Particle size of the nanoformulations did not changed after freeze-drying 
technique. 


















Benznidazole (BNZ) is the drug of choice for the treatment of Chagas disease in 
many countries. However, its low water solubility produces low and/or variable 
oral bioavailability. Thus, the aim of this work was to formulate micro- and 
nanoparticles based on Eudragit® RS PO and Eudragit® RL PO as a convenient 
approach to increase the dissolution rate of BNZ. The microparticles were 
obtained by means of spray-drying process while the nanoparticles were 
prepared through the nanoprecipitation technique and further freeze-drying. The 
results indicated that nanoparticles were obtained in 86% yield while 
microparticles were obtained in 68% yield. In both cases, the encapsulation 
efficiency of particles was greater than 78% while drug loading capacity was 
nearly 24% w/w and 18% w/w, after spray-drying and freeze-drying procedures, 
respectively. Images of scanning electron microscopy showed that the particles 
obtained by spray-drying and freeze-drying were in the micrometer and 
nanometer scale, respectively. FT-IR spectra of BNZ-loaded particles obtained 
by both methods showed characteristic bands of BNZ confirming that part of drug 
remained on their surface. Thermal analysis revealed that the drug crystallinity 
after both methods decreased. Physical stability evaluation of the nanoparticles 
confirmed that Pluronic® F68 was suitable to keep the particles size in a range of 
300 nm after 70 days storage at 4 ± 2 °C. In-vitro release studies showed 
increased dissolution rate of drug from the particles obtained by both methods 
respect to untreated BNZ. The kinetics of drug release in acid media followed the 
Higuchi kinetics indicating drug diffusion mechanism from particles. 
 

















Chagas disease, caused by the protozoan parasite Trypanosoma cruzi (T. cruzi) 
affects about 6 to 7 million people worldwide, mainly in Latin America [1]. Even 
though the disease was discovered more than hundred years ago, to these days 
there are only two drugs, nifurtimox and benznidazole (BNZ), to treat it [2]. BNZ 
is currently considered the trypanocidal drug of choice because of its better 
tolerability profile and possibly efficacy [3]. In particular, it is highly effective during 
the acute phase of the infection and in chronically infected children [4]. Moreover, 
BNZ treatment is recommended in congenital cases and reactive infections 
among all children and for patients up to 18 years old in the indeterminate chronic 
phase [5]. It is worth noting that, recently, BNZ was approved by FDA to treat 
patients 2-12 ages [6]. The etiological treatment is useful to prevent congenital 
infection by T. cruzi. Fabbro et al. showed that the relative risk of transmitting the 
infection is 25 times higher for untreated mothers than for those who received 
treatment before pregnancy [7]. However, it is important to highlight that BNZ, the 
first-line drug in the treatment of Chagas disease, it is practically insoluble in 
water (0.4 mg/mL) and, as a consequence, its solubility and dissolution rate may 
compromise the further chemotherapeutic performance [8,9]. To overcome such 
drawbacks, the administration of higher doses may be needed, resulting in the 
appearance of adverse effects [1,10]. Accordingly, treatment with BNZ is 
commonly discontinued in as much as 20% of cases due to the well-known side 
effects [11]. As a consequence, novel delivery systems are urgently needed to 













treatment for Chagas disease. In the last years, novel BNZ formulations have 
been developed including co-solvent systems [12], polymeric solid dispersions 
[13-15], microparticles [16] and complexation with cyclodextrin derivatives [17-
19]. In addition, as reviewed by Romero and Morilla, several nanosystems to treat 
Chagas disease were developed by using different carriers. Physicochemical 
properties of such formulations were discussed to determine their in-vitro and in-
vivo efficacy [20]. In particular, BNZ nanoformulations including liposomal 
formulations [21-24], nanocrystals [25,26] and polymeric nanoparticles [27] were 
described in the last years. However, the only chemotherapeutic treatment 
available for Chagas disease, to these days, is based on tablets, an unsuitable 
dosage form to treat neonates and young children [28]. BNZ was developed and 
produced as tablets by Roche until 2011 when production was discontinued. 
Then, this production was taken up by the Brazilian Pharmaceutical Laboratory 
of the State of Pernambuco (LAFEPE) and ELEA Laboratory (Argentine) [4]. 
ELEA Laboratory formulated BNZ into tablets of 50 and 100 mg (ABARAX®). Until 
recently, the 50 mg tablets were the only formulation available for children. Later, 
as a result of an alliance between the Drugs for Neglected Diseases initiative 
(DNDi) and LAFEPE, a pediatric dosage form (BNZ 12.5 mg tablets) was 
developed and a corresponding clinical trial (ClinicalTrials.gov Identifier: 
NCT01549236) was conducted in children weighing <20 kg. This pediatric 
formulation was registered in Brazil and in 2013 was included on the WHO's 
Essential Medicines List for children as a new dosage form indicated for children 
below 2 years old with Chagas disease [5,29,30]. However, in many occasions 
the pediatric population is still treated by fractioning those tablets according to the 













administration of sub-therapeutic or toxic doses [31]. In addition, both the stability 
and bioavailability of BNZ may be greatly reduced. In this regard, multi-particulate 
formulations may represent an attractive alternative for children below the age of 
6, as recommended by WHO [32]. These types of pharmaceutical dosage forms 
can be administered into the buccal cavity of the children or mixed with beverages 
before administration [33]. Therefore, in this study, multi-particulate systems 
based on Eudragit® RS PO and Eudragit® RL PO and loaded with BNZ were 
developed. BNZ nanoparticles were obtained by freeze-drying while BNZ 
microparticles were obtained by spray-drying. The solid state characterization of 
both nano- and microparticles was performed by means of thermal analysis 
(DSC), infrared spectroscopy (FT-IR) and scanning electronic microscopy (SEM). 
The influence of storage conditions on long-term stability of BNZ nanoparticles 
was evaluated at different temperatures in solution and also in a solid state. In 
addition, the release profile for each multi-particulate system was investigated.  
 
2. Materials and methods 
 
2.1. Materials 
BNZ (lot 9978 A; Laboratorio Elea, Buenos Aires, Argentina) was provided by 
Instituto Nacional de Parasitología, ANLIS Malbrán, Ministerio de Salud de la 
Nación (Buenos Aires, Argentina). Eudragit® RL PO and Eudragit® RS PO 
(copolymers of ethylacrylate, methylmethacrylate and methacrylic acid esterified 
with quaternary ammonium groups) and Sipernat® (specialty silica) were kindly 













nonionic surfactant, was kindly donated by BASF (Argentina). All the other 
reagents and chemicals were of analytical grade and used as received. 
2.2. Preparation of BNZ nanoparticles 
BNZ-loaded nanoparticles (NP) were prepared by nanoprecipitation and freeze-
drying. Firstly, pure polymer (Eudragit® RL PO or Eudragit® RS PO) or blend 
(Eudragit® RL PO/Eudragit® RS PO, 1:1 weight ratio) (0.025 g total weight) and 
BNZ (0.01 g) were dissolved in acetone (10 mL) (polymer:drug weight ratio 2.5:1); 
whereas that Pluronic® F68 (0.01875 g) was dissolved in distilled water (20 mL). 
The organic phase was injected on the aqueous phase using a syringe (10 mL) 
and needle (21G1, 0.80x25 mm) at constant flow rate (20 mL/h, Pump 11 Elite 
Infusion/Withdrawal Programmable Single Syringe, Harvard Apparatus, U.S.). 
The aqueous phase was maintained under moderate magnetic stirring (200 rpm) 
(IKA® C-MAG HS 7 digital, Germany). The resulting suspension was stirred at 
room temperature under fume hood for 8 h to allow the complete evaporation of 
the organic solvent. The suspension obtained was filtered through filter paper and 
the supernatant was frozen at -20 °C and freeze-dried (Freeze-Dryer RIFICOR 
model L-I-E300-CRT, Argentine) for 48 h. Powder obtained was stored at room 
temperature protected from light and moisture until use. Three formulations of NP 
were obtained in triplicate using Eudragit® RL PO, Eudragit® RS PO and the 
corresponding blend (1:1 weight ratio). These were namely NP-RL, NP-RS and 
NP-RL/RS, respectively. Blank particles (without BNZ) were prepared and used 
as references. 
 













BNZ-loaded microparticles (MP) were obtained by suspension and spray-drying. 
Firstly, Eudragit® RL PO, Eudragit® RS PO or blend (Eudragit® RL PO/Eudragit® 
RS PO, 1:1 weight ratio) (6.0 g total weight) and BNZ (2.4 g) were dissolved in 
absolute ethanol (60 mL) under moderate magnetic stirring (IKA® C-MAG HS 4 
digital, Germany) overnight. The polymer:drug weight ratio was 2.5:1. Then, this 
organic phase was added to a dispersion of Sipernat® (7.5% w/v) in distilled 
aqueous (540 mL) and left under magnetic stirring for 1 h. The sample was 
homogenized using a T18 Ultra-Turrax (IKA®-Werke GmbH & Co.KG) (17,500 
rpm, 5 min). The suspension resulting was maintained throughout the process 
under constant magnetic stirring (200 rpm) (IKA® C-MAG HS 4 digital, Germany) 
to ensure homogeneity while was fed into a Mini Spray Dryer Büchi B-290 (Büchi 
Labortechnik AG, Switzerland) through a two-fluid nozzle (0.70 mm inner 
diameter) in open-loop mode and co-current flow. The operating conditions were 
the following: air inlet temperature of 130 °C, atomizing air flow rate of 600 L/h, 
liquid flow rate of 1 mL/min, carrier gas flow rate (aspirator) of 35 m3/h and 
pressure of 4 bar. The resulting air outlet temperature was 65 °C. The dried 
powder was recovered from the glass collection vessel and weighed to determine 
the yield. Then, MP were stored in glass vials at room temperature protected from 
light and moisture until use. Three formulations of MP were obtained in triplicate 
using Eudragit® RL PO, Eudragit® RS PO and blend (1:1 weight ratio). These 
were namely MP-RL, MP-RS and MP-RL/RS, respectively. In addition, blank 
particles were also prepared. 
 














2.3.1. External morphology  
The external morphology of BNZ-loaded particles was visualized by scanning 
electron microscopy (SEM, JEOL JSM-5800LV Scanning Microscope, USA) 
operating at an accelerating voltage of 15 kV. Samples were previously sputter-
coated with a gold layer to make them conductive (Denton Vacuum, Desk II).  
 
2.3.2. Size and size distribution 
 
2.3.2.1. BNZ nanoparticles 
Size, size distribution and zeta potential of the NP were determined, before and 
after freeze-drying, by dynamic light scattering (DLS) using a NanoPartica SZ-
100 Horiba instrument (HORIBA Instruments Inc. California, USA). 
Measurements were conducted at a scattering angle of θ = 173° to the incident 
beam and at 25 °C. Results of size (intensity mean hydrodynamic diameter, Dh), 
size distribution (polydispersity index, PDI) and zeta potential (Z-pot) are 
expressed as mean ± S.D. of three independent samples. To evaluate the 
influence of the freeze-drying process on the Dh, NP (0.01 g) were dispersed in 
an aqueous solution of Tween® 80 (0.1% w/v, 15 mL), sonicated (10 min) and 
analyzed by DLS. The factor of variation of the Dh (fs) was determined by Equation 
(I): 
 
𝑓𝑠 =  
𝑆𝑓
𝑆𝑖














Where 𝑆𝑓 and 𝑆𝑖 is the Dh of the NP after and before the freeze-drying process, 
respectively. The results are expressed as mean ± standard deviation (S.D.) of 
three independent samples prepared under the same conditions. 
 
2.3.2.2. BNZ microparticles 
Size and size distribution of the MP were estimated by SEM. Images with 20X 
magnification were analyzed with an image analysis system (Image Pro-plus® 
software 6.0) to obtain the average size value of these MP. 
 
2.3.3. Yield, loading capacity and entrapment efficiency 
The yield (%) after freeze-drying and spray-drying processes was determined 





 ×  100  (II) 
 
Where 𝑊𝑃 is the total weight of BNZ-loaded particles obtained after drying 
process and 𝑊0 is the total initial weight of polymers, excipients and BNZ 
employed in their preparation. 
To determine the loading capacity (%LC) and the encapsulation efficiency (%EE), 
BNZ-loaded particles (0.01 g) of each sample were dissolved in absolute 
ethanol/distilled water (97/3 v/v) (5 mL) under magnetic stirring during 30 min. 
Then, an aliquot of this suspension (200 µL) was diluted with the same solvent 
up to a final volume of 5 mL. The BNZ concentration was determined by UV-
visible spectrophotometry (λ= 324 nm, UV-1800 Shimadzu UV-VIS 













40 µg/mL in ethanol/distilled water (97/3 v/v) (R2 > 0.9997). Measurements were 
performed in triplicate and results are expressed as mean ± S.D.  
The %LC of the BNZ-loaded particles was calculated according to Equation (III): 
 
%𝐿𝐶 =  
𝑊𝐵𝑁𝑍
𝑊𝑃
 ×  100  (III) 
 
Where, 𝑊𝐵𝑁𝑍 is the weight of BNZ in the particles and 𝑊𝑃 is the total weight of 
BNZ-loaded particles obtained. 





 ×  100  (IV) 
 
Where 𝐿𝐶𝑃  and 𝐿𝐶𝑇 are the experimental and theoretical loading capacity of the 
BNZ-loaded particles, respectively. 
 
2.3.4. Attenuated total reflectance/Fourier transform-infrared spectroscopy 
(ATR/FT-IR) 
ATR/FT-IR spectroscopy is a fast and versatile technique for determining 
interactions between BNZ and the corresponding polymers. Therefore, free BNZ, 
blank particles and BNZ-loaded particles obtained by both methods were 
analyzed by FT-IR (Nicolet iS5 FT-IR spectrometer, Thermo Scientific, USA) 
equipped with ATR (iD3 ATR, Thermo Scientific, USA) in the range between 4000 
and 600 cm−1 (16 scans, spectral resolution of 4.0 cm−1). FT-IR spectra were 














2.3.5. Thermal analysis 
The thermal analysis of free BNZ, polymers and BNZ-loaded particles was 
performed by differential scanning calorimetry (DSC, Model PT 1000 differential 
scanning calorimeter, Germany). Samples (∼5 mg) were loaded to aluminium 
pan, crimped, sealed and heated in a simple heating temperature ramp from 25 
to 200 °C at a rate of 10 °C/min under dry nitrogen atmosphere (flow rate 100 
mL/min). The different thermal transitions were analyzed. The crystallinity degree 






× 100%  (V) 
 
Where ∆𝐻𝑚−𝐵𝑁𝑍 is the value of melting enthalpy of BNZ in the particles and 
∆𝐻𝑐𝑚−𝐵𝑁𝑍 is the value of melting enthalpy of 100% crystalline BNZ. Values were 
normalized to the content of each one of the components in the particles. 
 
2.4. Physical stability studies 
According to ICH guidelines, the NP were stored in closed vials, protected from 
light, in a refrigerator (4 ± 2 oC) and in a close cupboard (25 ± 2 oC). The samples 
were evaluated in terms of particle size at 0, 7, 14, 21, 28, 35, 42, 56, 63, and 70 
days, respectively, and Z-pot at 0 and 70 days. All determinations were carried 
out in triplicate and the mean values and S.D. are reported (see 2.3.2.1.). 
 













The release of BNZ from the formulated NP and MP was carried out by using the 
dialysis bag method such as other published works with minor modifications [34]. 
For comparison, the release of untreated BNZ was also analyzed. Each sample 
containing 5 mg of BNZ was dispersed in 0.1 N HCl (pH 1.2, 10 mL). The resulting 
suspension was placed into a dialysis bag (regenerated cellulose tubing, 
molecular weight cut off = 12,000–14,000 g/mol) and placed in a beaker 
containing the release medium (0.1 N HCl, 100 mL). This volume of medium 
ensures sink conditions. System was maintained at 37 ± 1 °C under moderate 
magnetic stirring (200 rpm). At predetermined time intervals (10, 15, 20, 30, 45, 
60, 90, 120, 180, 240, 300, 360, 420 and 480 min) an aliquot of the release 
medium (4 mL) was withdrawn and it was replaced by fresh medium pre-heated 
at 37 °C to maintain sink conditions. The dissolved BNZ amounts in samples were 
quantified directly or by dilution with 0.1 N HCl using UV-visible 
spectrophotometer set to 324 nm (see 2.3.3.). Assays were carried out in 
triplicate and the results are expressed as mean ± S.D. The dissolution profiles 
were compared using the dissolution efficiency (DE) value at 30 min (DE30), 60 
min (DE60) and 120 min (DE120). Statistical analysis of the DE was performed 
using a one-way analysis of variance (ANOVA) followed by least significant 
difference using GraphPad Prism version 5.00 for Windows (GraphPad Software, 
Inc., USA). 
 
2.5.1. Kinetic of release 
Modeling and comparison of drug release profiles was conducted with DDSolver 













describing the release mechanism of BNZ from the particles, Higuchi model and 
Korsmeyer-Peppas model: 
 
Higuchi model  
𝐹 = 𝑘𝐻 . 𝑡
0.5  (VI) 
 
Where 𝐹 is percentage of drug released and 𝑘𝐻is the Higuchi release constant. 
The release rate is explained as a square root of the time-dependent process 
based on the Fickian diffusion. 
 
Korsmeyer–Peppas model 
𝐹 = 𝑘𝐾𝑃. 𝑡
𝑛  (VII) 
 
Where 𝑘𝐾𝑃  is the release constant incorporating structural and geometric 
characteristics of the drug dosage form and 𝑛 is the diffusional exponent 
indicating the drug release mechanism. The criterion for selecting the most 
appropriate model was based on a goodness-of-fit test. 
 
3. Results and discussion 
 
3.1. Characterization of BNZ nanoparticles 
As mentioned above, BNZ is practically insoluble in water (0.4 mg/mL) and, as a 
consequence, higher oral doses may be required to achieve a therapeutic drug 
concentration in the systemic circulation. Therefore, it is of utmost importance to 













nano/microparticulate systems may improve its solubility and dissolution [10]. 
One of the most widely applied techniques to formulate nanoparticulate systems 
is the nanoprecipitation or solvent displacement method. It is based on the 
interfacial precipitation on the nanoscale of a polymer after displacement of a 
semi-polar solvent, miscible with water from a lipophilic solution [35]. This 
methodology has been widely applied to obtain particles in the 100-300 nm range. 
It is mostly suitable for encapsulation of hydrophobic compounds that are soluble 
in ethanol or acetone [35]. These non-halogenated organic solvents are less toxic 
and more eco-friendly than halogenated organic solvents used in other 
encapsulation methods as the emulsion/solvent evaporation [27,36,37]. As 
carrier for the development of NP were selected Eudragit® RS PO and Eudragit® 
RL PO polymers. These polymers are amorphous, non-biodegradable, 
nonabsorbable, and nontoxic. In addition, cationic Eudragit® derivatives may 
interact with the negatively charged intestinal mucosa after the oral administration 
of Eudragit®-based drug delivery systems [16,38]. Thus, BNZ and the 
corresponding polymers were dissolved in acetone (solvent) and added to a 
water/Pluronic® F68 solution (non-solvent). After the diffusion of acetone into the 
non-solvent phase, it was observed the appearance of a white precipitate 
suggesting that both the polymer and the hydrophobic BNZ became insoluble in 
contact with the non-solvent phase. In general, the nanoprecipitation is a process 
of high surface energy and, as a consequence, the newly formed nanoparticles 
may be agglomerated. Thus, Pluronic® F68 was used as steric stabilizer. The 
selection of this surfactant was based on previous reports that showed that 
smaller nanoparticles were obtained using Pluronic® F68 in comparison with 













nanosuspension, a solidification technique as freeze-drying was applied to obtain 
the corresponding powder. Solid form is more desirable than liquid form, as 
reaction rates of physical and chemical interactions are slower in solid state. 
However, freeze-drying often produces changes on nanoparticle properties, 
which may affect its size due to particle aggregation under cryogenic stress 
condition and compression during the formation of ice crystals in the internal 
water phase [40]. Thus, a cryo-protectant may be needed to inhibit interactions 
between nanoparticles during the freezing process and thus preserve 
redispersibility [41]. However, Pluronic® F68, an ABA triblock copolymer 
consisting of hydrophilic polyoxyethylene (PEO) and hydrophobic 
polyoxypropylene (PPO), is a stabilizer that can prevent the agglomeration of the 
particles during freeze-drying [42]. In this regard, Lee and Lin [43] assayed the 
effects of different surfactants (HCO-60, sodium dodecyl sulfate, Tween® 80, 
PEG 400, Pluronic® F68, and Pluronic® F127) on the conformational stability and 
structural similarity of a hormone in lyophilized forms. The results indicated the 
most optimal stabilization effect of Pluronic® F68. This effect might be attributed 
to its ability to protect hormone from dehydration and thermal stresses during 
lyophilization due to it is a much larger molecule with longer hydrophilic and 
hydrophobic chains is thought to play an important role to prevent the interfacial 
induced adsorption [43]. Herein, the stirring speed (200 rpm) at room temperature 
was found to be enough to prepare NP in a range of 200-300 nm with narrower 
size distribution.  
According to the literature, an increased particle size after lyophilization is 
frequently observed [44,45]. However, in this study the results of DLS analysis 













prepared nanosystems. Thus, the range of the sizes of Dh, before and after 
freeze-drying of NP, were found to be around 201-250 nm and 242-281 nm, 
respectively (Table 1). The increase in particle sizes after freeze-drying was tiny 
with fs value of around 1, demonstrating the freeze-drying process did not lead to 
significant NP aggregation (Table 1). Regarding size distribution, PDI value in the 
range of 0.15-0.3, indicates size homogeneity for submicron particles. Thus, all 
formulations showed PDI value below 0.2 before and after freeze-drying, 
indicating size homogeneity (Table 1). In addition, surface charge of NP was 
determined by the Z-pot. It should be note that Eudragit® is positively charged 
due to the presence of quaternary ammonium groups. Therefore, all formulations 
showed positive Z-pot values from +24 to +37 mV before and after freeze-drying 
(Table 1). These results are agreement with the literature [27,46,47]. The high 
charges can prevent aggregation by repulse particles with each other due to 
electrostatic stabilization induced by the cationic copolymer able to induce stable 
formulations [27]. Moreover, the positively charged NP could be attached to the 
negatively charged epithelial mucin layer in the gastrointestinal tract which in turn 
would improve drug oral bioavailability [48].  
The shape and surface morphology of the NP were observed by means of SEM, 
a very useful technique to analyze particles > 100 nm with a resolution of 5 nm, 
collecting information related with the size, surface and shape [49]. As seen in 
Fig. 1C, BNZ raw material presented a prismatic form with crystals of variable 
sizes such as those observed by Palmeiro-Roldán et al. [50]. In contrast, NP were 
found to be in the nanometer scale (< 1 m) and partially adhered by Pluronic® 













crystals (Fig. 1 C) were not visualized on the surface of the nanoparticulate 
system.  
 
Insert Table 1. 
 
3.2. Characterization of BNZ microparticles 
On the other hand, and using the same cationic polymers, MP were prepared by 
means of spray-drying process. As known, it is, probably, the most convenient 
tool to encapsulate active materials within different types of carriers including 
biodegradable polymers [51]. It is an attractive alternative to conventional 
techniques since it is a single-step process, shorter and cheaper compared to 
other drying processes commonly used in industry such as freeze-drying, 
because it does not involve deep cooling, usually associated with great energy 
consumption. It is worth mentioning that, compared to freeze-drying, spray-drying 
is up to 30-50 times cheaper [52,53]. The analysis of MP was performed using 
Image Pro-plus® software 6.0. As seen in Fig. 1A, spherical particles in a 
micrometer scale with a smooth surface were obtained. Media size of MP-RL, 
MP-RS and MP-RL/RS was 0.87 (± < 0.01) m, 1.08 (± 1.16) m and 1.26 (± < 
0.01) m, respectively. These results are in agreement with the findings of the 
previous studies. Thus, Rabbani and Seville [54], who produced dry powders 
suitable for inhalation containing β-estradiol by spray-drying using a Mini Spray 
Dryer B-290 with a 0.7 mm two-fluid nozzle. The mean particle size of the 
resultant microparticles was between 2.5 and 7 m, making them suitable 
pulmonary administration [54]. In addition, Ní Ógáin et al. [53] described the 













using the same drying equipment [55]. On the other hand, García et al. [56] 
developed chitosan-pectin-carboxymethylcellulose microspheres by spray-drying 
to improve the oral absorption of albendazole as a model drug. The mean 
diameter of the microspheres was 2.8 m [56]. 
 
Insert Figure 1. 
 
3.3. Yield, loading capacity and entrapment efficiency  
The production yields obtained during the formulation process were nearly 86% 
for NP (Table 1). In agreement with the bibliography, nanoprecipitation is one of 
the most suitable techniques to prepare solid colloidal particles in the range of 
nanometer [57]. In this study, the selection of the polymers and stabilizer, the 
stirring speed and the freeze-drying process confirmed the robustness of the 
methodology to obtain NP in high yield [34,39]. On the other hand, spray-drying 
process exhibit several advantages over other solvent evaporation procedures, 
as already described. However, one of the main challenges of such process is 
the moderate yield obtained on the laboratory scale (20-70%) when conventional 
dryers are used [58-60]. In this work, MP were obtained in a 68%, approximately 
(Table 1). This moderate yield could be due to the powder tend to adhere to the 
glass wall of cyclone, as observed during the drying process [59]. This is 
consistent with the work of Rassau et al. [61] who informed yields nearly 60% 
during the preparation microparticles based on Eudragit® and loaded with 
ketoprofen. Another key parameter during the incorporation of drugs into 
polymeric particles is the %EE. Usually, it is based on the selected encapsulation 













Herein, regardless of the preparation method and the polymeric composition the 
%EE was high on all formulations (> 78.8%), as seen in Table 1. This is 
consistent with the literature data due to both nanoprecipitation/freeze-drying and 
spray-drying can yield high %EE of lipophilic drugs within polymeric carriers 
[62,63]. Moreover, %LC values were around 20% (18% and 23% in NP and MP, 
respectively) indicating a moderate drug loading capacity of all systems (Table 
1). In this regard, a considerable amount of NP or MP would be needed to deliver 
the required dose in order to achieve the desired pharmacological activity. 
However, the enhancement of BNZ dissolution rate (Fig. 3) may lead to improve 
the oral bioavailability and, therefore, lower doses of BNZ might be administered, 
minimizing its adverse effects. [8]. In any case, to confirm this postulate, it is 
necessary to evaluate the in-vivo performance of such formulation in comparison 
with the non-encapsulated drug. 
 
3.4. Solid state characterization of the BNZ-loaded particles 
 
3.4.1 Attenuated total reflectance/Fourier transform-infrared spectroscopy 
(ATR/FT-IR) 
To analyze the potential interactions between groups of BNZ with the backbone 
of Eudragit® after both encapsulation processes, the samples of the different 
BNZ-loaded particles were studied by ATR/FT-IR spectroscopy and compared to 
the spectrum of blank particles and free BNZ. Blank particles showed 
characteristic bands of pure polymers (Figure 1S). Free BNZ showed the 
characteristic bands of (i) NH deformation at 1565 cm−1, characteristic of an 













1318 cm−1. The band due to stretching vibrations of N-H is at 3,330 cm−1. In 
addition, the cluster of bands at 3180, 3160, 3120, 3090 and 3000 cm−1 suggests 
symmetrical and asymmetrical stretching vibrations for the methylene in the 
benzyl group and stretching of the aromatic C-H [18] (Figure 1S). Regarding the 
NP and MP, the intensity and shape of the bands between 1600 and 1000 cm−1 
did not exhibit significant modifications (Figure 1S). However, a significant 
reduction of relative intensity of the peaks in the region of 3300-3000 cm−1 was 
clearly detected. It could be due to the formation of H-bonding between the N-H 
group of BNZ and the C=O group of the polymer. These findings are in agreement 
with those results reported by Lima et al. [14] and dos Santos-Silva et al. [27], 
who showed similar modifications of the FT-IR spectra of BNZ by interactions 
with other polymers [14,27].  
 
3.4.2 Thermal analysis  
DSC is a good standard technique to elucidate the crystalline or amorphous 
nature of drugs associated at a polymeric matrix after an encapsulation process. 
All the BNZ-loaded particles showed a characteristic glass transition temperature 
(Tg) of Eudragit® at 49-50 °C, the thermal behavior being identical to that of pure 
polymer [64] (Table 2). The thermogram of BNZ showed an endothermic peak at 
195 °C (ΔHm = 118.4 J/g) that was considered as 100% crystallinity, as reported 
in the literature [14,65]. BNZ-loaded particles obtained by both methods exhibited 
the Tm of BNZ at 195-197 °C with %CBNZ < 25% in all cases, suggesting that the 
drug underwent partial amorphization in polymeric matrix during the 
encapsulation process (Table 2). These data are in agreement with the work of 













formation of polyelectrolyte complexes with other polymethacrylate derivatives 
[16]. 
 
Insert Table 2. 
3.5. Physical stability studies 
The physical stability of a nanosystem is of particular interest when the solution 
is freeze-dried [66]. Thus, in this study, the particle size of the nanoformulations 
was evaluated before and after drying processes over a period of 70 days, at both 
4 ± 2 °C and 25 ± 2 °C (Fig. 2). As seen in Fig. 2A and Fig. 2B, a size change 
was observed in the NP placed at room temperature. In solution, the particle size 
increased up to nearly 920 nm using Eudragit® RS PO as a carrier from its original 
size, around 200 nm (Fig. 2A). After freeze-drying, the analysis of the 
nanosystems revealed that the NP were in the size range of 650 to 750 nm (Fig. 
2B). This finding might be attributed, mainly, to an increased interaction of the NP 
under storage at room temperature, probably due to an incomplete coverage of 
the NP surfaces by means of the stabilizer leading, as a consequence, to the 
formation of new agglomerates. In this regard, Reddy et al. [67] found that particle 
size of tamoxifen citrate-loaded nanoparticles increased under storage at 50 oC 
during 30 days, as a result of particle aggregation [67]. On the other hand, it was 
observed that NP placed in solution at 4 ± 2 °C changed its particle size from 
around 200 nm (0 day) to 400 nm (70 days), depending the type of polymer (Fig. 
2C). It could be related, probably, to the phenomena of crystal growth and/or the 
formation of aggregates in solution. In contrast, freeze-dried nanosystems 
displayed the best stability (Fig. 2D). Thus, NP formulated with Eudragit® RL PO, 













particle size of 301.9 nm, 242.4 nm, and 282.4 nm, respectively at 0 days while 
at 70 days the particle size was 320.9 nm, 270.5 nm, and 303.4 nm, respectively 
(Fig. 2D). Clearly, under this storage condition, NP exhibited a stable behavior, 
probably related with the absence or a very small influence of the Ostwald 
ripening [68]. It is worth mentioning that Quintanar-Guerrero et al. [69] described 
an aggregation of poly(D,L-lactic acid) nanoparticles, after freeze-drying, by using 
Pluronic® F68 as stabilizer. However, in this case such polymer was able to 
stabilize the NP under storage, at least for 70 days. Therefore, it could be 
suggested that Pluronic® F68 is a convenient approach to avoid agglomeration 
when freeze-dried samples are placed at 4 ± 2 °C and then dispersed in water. 
From the data obtained, it can be suggested that NP placed at low temperature 
are more stable, in terms of particle size, than the corresponding NP placed at 
room temperature, regardless of the Eudragit® used. On the other hand, the Z-
pot values slightly changed after 70 days placed at both 4 ± 2 °C and 25 ± 2 °C, 
indicating that the NP surface was not greatly modified after freeze-drying 
process suggesting that these data are not related to the particle size stability 
results. 
 
Insert Figure 2. 
 
3.6. In-vitro drug release 
Release studies were performed in HCl 0.1 N (pH 1.2) at 37 °C to simulate the 
pH gastric physiological due to these particles were formulated to be orally 
administered. As compared to the raw BNZ, the results showed enhanced BNZ 













similar profiles in the three formulations and differences were not statistically 
significant (p > 0.05) (Fig. 3A). As seen in Table 3, DE30, DE60 and DE120 values 
of MP were greater that non-encapsulated BNZ. Differences were statistically 
significant (p < 0.001) (Table 3). This could be due to that part of BNZ remained 
on the surface of the MP, according to SEM image (Fig. 1A) and FT-IR spectra, 
leading to a rapid release and after dissolution of BNZ in the medium of similar 
gastric pH (Fig. 3A). NP also showed dissolution profile higher than free-BNZ 
(Fig. 3B) with DE30, DE60 and DE120 values greater that non-encapsulated BNZ. 
Differences were statistically significant (p < 0.001) (Table 3). In comparison with 
these findings, other researchers obtained promising results using liposomal 
formulations with the purpose of increasing the amount of BNZ delivered to 
infected Kupffer cells, which naturally phagocyte multilamellar liposomes. Such 
formulations were prepared by employing hydrogenated phosphatidylcholine 
from soybean (HSPC): Cholesterol (Chol): distearoyl-phosphatidylglycerol 
(DSPG) (molar ratio 2:2:1) as lipid matrix [21,23]. The drug loading obtained was 
of 2 g BNZ/100 g total lipids at a total lipid concentration of 20-30 mM. In-vitro 
release of drug after 60 min at 450-fold dilution in buffer at 37 °C showed that the 
amount of drug associated to liposomes was reduced from 2 to 0.25 g BNZ/100 
g total lipids at a rate of 65% (drug lost) min-1 at the first minute followed by 0.4% 
(drug lost) min-1 for the next 59 min. In our study, the higher dissolution rate of 
drug from the particles could be due to the size reduction of the drug, increase of 
surface area and reduction of the drug crystallinity after processes [14,70] (Table 
2). Thus, as the dissolution rate in the gastrointestinal tract of poor water-soluble 













bioavailability, enhanced dissolution could lead to an increase in BNZ oral 
bioavailability [19].  
 
Insert Figure 3. 
 
3.6.1. Kinetic of drug release 
The calculated fitting parameters of the kinetic models after applying a non-linear 
regression analysis are summarized in Table 3. To reveal the release mechanism 
of BNZ from particles, the dissolution profiles were fitted by two different kinetic 
models: Higuchi and Korsmeyer-Peppas. The values of R2adj were higher for the 
Higuchi model (0.9458-0.9615) that Korsmeyer-Peppas (0.8350-0.9247) in all 
formulations (Table 3). The Higuchi model is an invaluable tool in developing a 
controlled drug delivery [71]. Higuchi was the first to derive an equation to 
describe the release of a drug from an insoluble matrix as the square root of a 
time-dependent process based on Fickian diffusion [72]. This equation addresses 
the release rate of a drug from a matrix, usually a polymer, where the loading of 
drug exceeds its solubility in the matrix into a surrounding fluid [71]. On the other 
hand, the Korsmeyer-Peppas model is widely used to indicate the appropriate 
release mechanism between different mechanisms [73]. In this model, n values 
≤ 0.43 indicate that occurs Fickian diffusion. Conversely, if n ≥ 0.85 the diffusion 
comprises super-Case II transport where the drug release is purely governed by 
polymer relaxation. Finally, if n is between these values (0.43 and 0.85), 
anomalous diffusion is predominant, i.e., non-Fickian diffusion process, where 
the release can be attributed to a combination of drug diffusion and polymer chain 













in the 0.7016–0.7120 (Table 3) range indicating that the drug release could be 
accomplished by diffusion of the drug from matrix and polymer chain relaxation. 
On the other hand, the MP obtained by spray-drying showed n values ≥ 0.85 
(0.8500-0.9721) (Table 3) indicating that the drug release could be produced by 
polymeric relaxation (Super Case II). In agreement with other reports dealing with 
the formulation of BNZ microparticles, in this work the best fitting to the Higuchi 
model indicates that the release of the drug from the particles was by diffusion 
from the polymer matrix. 
 
Insert Table 3. 
 
4. Conclusions 
In this study, it was demonstrated for the first time that both 
nanoprecipitation/freeze-drying and suspension/spray-drying are effective 
methods to obtain BNZ nano- and microparticles, respectively, in relatively high 
yields. It is worth mentioning that BNZ nanoparticles were obtained within the size 
range of 200-300 nm and the stabilizer was able to keep the nanoparticle size 
and zeta potential during the freeze-drying process. In addition, the physical 
stability evaluation of the BNZ nanoparticles indicated that Pluronic® F68 was 
suitable to keep the particle size in a range of 300 nm after 70 days storage at 4 
± 2 °C. FT-IR studies of the BNZ particles suggested some interactions between 
the drug and the polymers while thermal analysis revealed that the drug 
crystallinity decreased after both freeze- and spray-drying procedures. All these 
factors allowed to enhance dissolution efficiency of BNZ from particles in 













profiles indicates that the release of the drug from the particles was by diffusion 
from the polymer matrix. Thus, in agreement with urgent needs for Chagas 
disease pediatric treatments, all these formulations obtained in powder form 
would allow dose flexibility to suit the dosing requirements across all age groups. 
Taking in account these results, further in-vitro/in-vivo studies in animal infection 
model will be performed in the near future to analyze whether these polymeric 
multiparticulate BNZ formulations may exhibit a better biological activity in 
comparison with the raw drug. 
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Fig. 1. SEM micrographs of BNZ-loaded particles obtained by spray-drying (A) 
and freeze-drying (B) and free BNZ (raw material) (C). (A) MP-RS, (B) NP-RS. 




















Fig. 2. Stability study of nanoparticles: Particles before (A) and after freeze-drying 
(B) stored at 25 ± 2 °C; and particles before (C) and after freeze-drying (D) stored 
at 4 ± 2 °C. *Statistically significant increase of hydrodynamic diameter with 




Fig. 3. BNZ cumulative dissolution percentage from polymeric particles obtained 
by spray-drying (MP-RL, MP-RS and MP-RL/RS) and free BNZ (A) and freeze-



































Table 1. Properties of the BNZ-loaded particles obtained by different methods 
and size, size distribution and Z-potential of the particles obtained by 
nanoprecipitation before and after freeze-drying. 
a %LC, loading capacity. 
b %EE, encapsulation efficiency. 
c Dh, intensity mean hydrodynamic diameter. 
d PDI, polydispersity index. 
e Z-pot, zeta-potential.  
f fs, factor of variation of the Dh after and before the freeze-drying process.  
 
  
Formulation Method of obtaining %LC a  
(± S.D.) 
%EE b  
(± S.D.) 
Yield (%)   
(± S.D.) 
Before freeze-drying After freeze-drying fs f 
























































































































Table 2. Thermal analysis of BNZ, polymers and BNZ-loaded particles obtained 
by freeze-drying and spray-drying. 
 
 
a Tm (°C), melting temperature, expressed in °C. 
b Tg (°C), glass transition temperature, expressed in °C. 
c ΔHm (J/g), enthalpy of melting, expressed in J/g. 
d ΔHg (J/g), enthalpy of glass transition, expressed in J/g. 









Sample Tm (°C) a Tg (°C) b ΔHm (J/g) c ΔHg (J/g) d %CBNZ e 
BNZ 195 - 118.4 - 100 
Eudragit® RL PO - 50 - 22.8 - 
Eudragit® RS PO - 51 - 27.3 - 
NP-RL 195 49 5.1 90.7 24.3 
NP-RS 195 49 2.7 30.7 12.8 
NP-RL/RS 196 47 0.9 88.7 4.4 
MP-RL 197 49 0.3 8.3 1.0 
MP-RS 195 49 5.8 36.4 20.5 




























Table 3. Dissolution efficiency values of free BNZ and BNZ-loaded particles and 
curve fitting analysis. 
a DE30, dissolution efficiency at t = 30 min. 
b DE60, dissolution efficiency at t = 60 min. 
a DE120, dissolution efficiency at t = 120 min. 
Higuchi model: kH, release rate constant. 
Korsmeyer–Peppas model: analysis was conducted for Mt/M∞ ≤ 0.6; kKP, kinetic constant; n, 
release exponent. 





Formulation  ED30 a 
 
ED60 b ED120 c Higuchi model Korsmeyer-Peppas model 
kH R2adj kKP n R2adj 
BNZ (5 mg) 5.50 12.34 27.21 - - - - - 
NP-RL 20.76* 37.30* 62.60* 5.0288 0.9615 1.7559 0.7016 0.8690 
NP-RS 19.04* 34.23* 62.09* 4.9593 0.9575 1.6943 0.7120 0.8569 
NP-RL/RS  21.76* 39.07* 67.09* 5.0995 0.9544 1.7585 0.7055 0.8350 
MP-RL 13.29* 24.23* 49.78* 4.5486 0.9467 0.7204 0.8500 0.9247 
MP-RS 12.02* 25.57* 49.65* 4.4304 0.9458 0.3131 0.9721 0.8526 
MP-RL/RS 14.29* 29.55* 52.48* 4.6231 0.9508 0.4084 0.9309 0.8484 
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